Department of Ophthalmology

Clinical Trials

Are you a patient?

Here at the USC Roski Eye Institute, we offer patients the opportunity to participate in clinical trials and research. Please see our active clinical trials below. Contact our clinical trial navigators for opportunities that may be suitable for you.

Protocol Name Study Title Link to Clinical Trials
HZNP-TEP-402 A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab https://clinicaltrials.gov/ct2/show/NCT05002998
VRDN-001-101 A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and subjects with thyroid eye disease (TED) https://clinicaltrials.gov/ct2/show/NCT05176639
ACELYRIN-21103 A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis https://clinicaltrials.gov/ct2/show/NCT05384249
OTX-TIC-2020-201 A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) https://clinicaltrials.gov/ct2/show/NCT05335122
NAC Attack A Phase-3, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa Study Details | Oral N-acetylcysteine for Retinitis Pigmentosa | ClinicalTrials.gov
KOWA-321-301 A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Patients with Fuchs Endothelial Corneal Dystrophy https://clinicaltrials.gov/study/NCT05795699
KOWA-321-303 A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy https://clinicaltrials.gov/study/NCT05826353
PHOENIX Phase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy https://clinicaltrials.gov/study/NCT05949593
ESK-001-014 A Proof-of-Concept, Randomized, Double-Masked Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Active Noninfectious Intermediate, Posterior, or Panuveitis (OPTYK-1) https://clinicaltrials.gov/study/NCT05953688

 

Contact Information:

Research Coordinator: Mariana Edwards
P: 323-442-6490
E: mariana.edwards@med.usc.edu